Success Story: NIW Approved in 47 Days for Cancer Medicine Outcomes Research Focused on Therapy Safety

Posted by wegreened on March 24, 2026 in NIW, Medicine (Pharmaceutics, Pharmacology, Oncology, Pharmacognosy, Biomedical Engineering, Biomedicine)

Client’s Testimonial:

"Thank you for your dedication and all your help with my case."

On January 17^th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Physician in the Field of Cancer Medicine (Approval Notice).

General Field: Cancer Medicine

Position at the Time of Case Filing: Physician

Approval Notice Date: January 17^th, 2026

Processing Time: 1 month, 16 days (Premium Processing Upgrade Requested)

Case Summary:

Cancer therapies only deliver their full benefit when clinicians can weigh effectiveness against complications that may compromise quality of life or interrupt treatment. When adverse effects are undercharacterized and when real-world outcomes are not rigorously tracked, patients can face avoidable hospitalizations, delayed care, and reduced survival. The client’s work targets that gap by collecting and analyzing data from cancer research studies to assess the efficacy and complications of cancer therapies, helping strengthen evidence-based treatment decisions and improve outcomes for patients in the United States.

The client serves in a physician and research role within a U.S.-based healthcare environment, while also holding an academic appointment at a U.S.-based medical institution. In presenting this I-140 National Interest Waiver (NIW) petition, North America Immigration Law Group (Chen Immigration Law Associates) framed the proposed endeavor as a practical, ongoing line of work that supports better clinical decision-making across cancer care. The petition was approved in just 47 days, reflecting a record that clearly connected the client’s research direction to national-scale healthcare needs.

To show that the client is well-positioned, the case emphasized sustained contributions and independent recognition. Rather than presenting these metrics as merely self-evident, we translated them into a clear narrative of impact. We organized the evidence around objective indicators that clearly demonstrate their real-world influence:

Scholarly output: more than 10 peer-reviewed journal articles
Citation reliance: over 400 citations, including multiple papers that ranked among the top 10% most cited for their publication years

These markers were tied to how the field functions. Repeated publication in highly regarded peer-reviewed venues signals consistent success under rigorous evaluation. Citations, particularly when contextualized by citation percentiles across publication years, indicate that other researchers are using the work as a foundation rather than merely acknowledging it. Presented together, the record supported the conclusion that the client’s contributions are both credible and meaningfully relied upon in clinical medicine.

USCIS approved the NIW petition without any RFE issues, recognizing a well-supported endeavor in cancer medicine that is positioned to improve patient outcomes by strengthening how therapy efficacy and complications are measured and understood. We congratulate the client on this important milestone and look forward to the continued impact of the client’s research in advancing cancer care in the United States.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Sixty-four Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.

Track Record of Success EB-1 and NIW Approvals

(2012.01 - 2025.12)

Category	Approval or Refund^®		Approval or Refiling^TM
	Approval or Refund^®
Category	Approved Sum	Success Rate	Approved Sum	Success Rate
NIW	42,047	99%	5,258	97%
EB1A	9,218	91%	4,534	86%
EB1B	1,488	98%	448	93%
Total	52,753	98%	10,240	92%